These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 31077910)

  • 21. Tuberculosis and its Treatment: An Overview.
    Bansal R; Sharma D; Singh R
    Mini Rev Med Chem; 2018; 18(1):58-71. PubMed ID: 27553018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pyrido[1,2-a]benzimidazole-based agents active against tuberculosis (TB), multidrug-resistant (MDR) TB and extensively drug-resistant (XDR) TB.
    Pieroni M; Tipparaju SK; Lun S; Song Y; Sturm AW; Bishai WR; Kozikowski AP
    ChemMedChem; 2011 Feb; 6(2):334-42. PubMed ID: 21259445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Opportunities and challenges of using five-membered ring compounds as promising antitubercular agents.
    Yan M; Xu L; Wang Y; Wan J; Liu T; Liu W; Wan Y; Zhang B; Wang R; Li Q
    Drug Dev Res; 2020 Jun; 81(4):402-418. PubMed ID: 31904877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy.
    Kumar Sahoo S; Maddipatla S; Nageswara Rao Gajula S; Naiyaz Ahmad M; Kaul G; Nanduri S; Sonti R; Dasgupta A; Chopra S; Madhavi Yaddanapudi V
    Bioorg Med Chem; 2022 Jun; 64():116777. PubMed ID: 35487101
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extensively drug-resistant (XDR) tuberculosis: an old and new threat.
    Fattorini L; Migliori GB; Cassone A
    Ann Ist Super Sanita; 2007; 43(4):317-9. PubMed ID: 18209265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New tuberculosis drugs on the horizon.
    Cole ST; Riccardi G
    Curr Opin Microbiol; 2011 Oct; 14(5):570-6. PubMed ID: 21821466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent progress in the drug development of coumarin derivatives as potent antituberculosis agents.
    Keri RS; Sasidhar BS; Nagaraja BM; Santos MA
    Eur J Med Chem; 2015 Jul; 100():257-69. PubMed ID: 26112067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent advances and challenges of revolutionizing drug-resistant tuberculosis treatment.
    Wei X; Yue L; Zhao B; Jiang N; Lei H; Zhai X
    Eur J Med Chem; 2024 Nov; 277():116785. PubMed ID: 39191032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naphthoquinones isolated from Diospyros anisandra exhibit potent activity against pan-resistant first-line drugs Mycobacterium tuberculosis strains.
    Uc-Cachón AH; Borges-Argáez R; Said-Fernández S; Vargas-Villarreal J; González-Salazar F; Méndez-González M; Cáceres-Farfán M; Molina-Salinas GM
    Pulm Pharmacol Ther; 2014 Feb; 27(1):114-20. PubMed ID: 23968826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The resumption of consumption -- a review on tuberculosis.
    Ducati RG; Ruffino-Netto A; Basso LA; Santos DS
    Mem Inst Oswaldo Cruz; 2006 Nov; 101(7):697-714. PubMed ID: 17160276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DFT based QSAR/QSPR models in the development of novel anti-tuberculosis drugs targeting Mycobacterium tuberculosis.
    Rajkhowa S; Deka RC
    Curr Pharm Des; 2014; 20(27):4455-73. PubMed ID: 24245759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. QSAR based design of new antitubercular compounds: improved isoniazid derivatives against multidrug-resistant TB.
    Martins F; Ventura C; Santos S; Viveiros M
    Curr Pharm Des; 2014; 20(27):4427-54. PubMed ID: 24245762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New nitrofurans amenable by isocyanide multicomponent chemistry are active against multidrug-resistant and poly-resistant Mycobacterium tuberculosis.
    Krasavin M; Parchinsky V; Kantin G; Manicheva O; Dogonadze M; Vinogradova T; Karge B; Brönstrup M
    Bioorg Med Chem; 2017 Mar; 25(6):1867-1874. PubMed ID: 28214232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, biological evaluation, and structure-activity relationships for 5-[(E)-2-arylethenyl]-3-isoxazolecarboxylic acid alkyl ester derivatives as valuable antitubercular chemotypes.
    Pieroni M; Lilienkampf A; Wan B; Wang Y; Franzblau SG; Kozikowski AP
    J Med Chem; 2009 Oct; 52(20):6287-96. PubMed ID: 19757815
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
    Poce G; Cocozza M; Consalvi S; Biava M
    Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis.
    Rakesh ; Bruhn DF; Scherman MS; Woolhiser LK; Madhura DB; Maddox MM; Singh AP; Lee RB; Hurdle JG; McNeil MR; Lenaerts AJ; Meibohm B; Lee RE
    PLoS One; 2014; 9(2):e87909. PubMed ID: 24505329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of the socio-demographic and clinical features of pulmonary TB patients infected with sub-lineages within the W-Beijing and non-Beijing Mycobacterium tuberculosis.
    Hu Y; Mathema B; Zhao Q; Zheng X; Li D; Jiang W; Wang W; Xu B
    Tuberculosis (Edinb); 2016 Mar; 97():18-25. PubMed ID: 26980491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Management of multidrug-resistant tuberculosis].
    Tritar F; Daghfous H; Ben Saad S; Slim-Saidi L
    Rev Pneumol Clin; 2015; 71(2-3):130-9. PubMed ID: 25153927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New potential drug leads against MDR-MTB: A short review.
    Gatadi S; Nanduri S
    Bioorg Chem; 2020 Jan; 95():103534. PubMed ID: 31884135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.